BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-7.42%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$5.38B
AUM Growth
+$5.38B
(-8.2%)
Cap. Flow
+$102M
Cap. Flow
% of AUM
1.9%
Top 10 Holdings %
Top 10 Hldgs %
41.73%
Holding
223
New
22
Increased
133
Reduced
36
Closed
13
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
$21.9M |
| 2 |
Glaukos
GKOS
|
$18.4M |
| 3 |
Arvinas
ARVN
|
$17.4M |
| 4 |
Agios Pharmaceuticals
AGIO
|
$14.4M |
| 5 |
Becton Dickinson
BDX
|
$12.9M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$75.9M |
| 2 |
Gilead Sciences
GILD
|
$32.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
$22.3M |
| 4 |
Teladoc Health
TDOC
|
$20M |
| 5 |
AVDR
Avedro, Inc Common Stock
AVDR
|
$15.8M |
Sector Composition
| 1 | Healthcare | 94.28% |
| 2 | Industrials | 0.53% |
| 3 | Technology | 0.51% |
| 4 | Financials | 0.07% |
| 5 | Consumer Discretionary | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $499M | 9.27% | 8,321,914 +364,786 | +5% | +$21.9M |
|
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $297M | 5.53% | 3,298,474 -247,970 | -7% | -$22.3M |
|
3
Incyte
INCY
$16.5B
| $274M | 5.1% | 3,696,200 -1,450 | -0% | -$108K |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $242M | 4.5% | 1,429,139 +8,650 | +0.6% | +$1.47M |
|
|
SAGE
5
DELISTED
Sage Therapeutics
SAGE
| $183M | 3.4% | 1,303,504 -17,900 | -1% | -$2.51M |
|
|
RDUS
6
DELISTED
Radius Health, Inc.
RDUS
| $177M | 3.29% | 6,876,885 +36,100 | +0.5% | +$930K |
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $158M | 2.94% | 1,965,072 +37,678 | +2% | +$3.03M |
|
8
Esperion Therapeutics
ESPR
$448M
| $155M | 2.89% | 4,241,461 +184,050 | +5% | +$6.75M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $134M | 2.49% | 1,366,528 +25,100 | +2% | +$2.46M |
|
10
Halozyme
HALO
$8.56B
| $124M | 2.31% | 8,014,356 -233,504 | -3% | -$3.62M |
|
|
11
Agios Pharmaceuticals
AGIO
$2.19B
| $116M | 2.15% | 3,571,554 +443,420 | +14% | +$14.4M |
|
12
argenx
ARGX
$43.6B
| $110M | 2.05% | 973,239 +28,600 | +3% | +$3.24M |
|
|
CELG
13
DELISTED
Celgene Corp
CELG
| $108M | 2% | 1,085,600 -764,400 | -41% | -$75.9M |
|
14
Intuitive Surgical
ISRG
$170B
| $94.8M | 1.76% | 175,645 +7,163 | +4% | +$3.87M |
|
15
Abbott
ABT
$231B
| $91.9M | 1.71% | 1,098,114 +140,519 | +15% | +$11.8M |
|
16
Medtronic
MDT
$119B
| $87.7M | 1.63% | 807,638 +28,227 | +4% | +$3.07M |
|
|
ALDR
17
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $84.7M | 1.58% | 4,492,466 +373,660 | +9% | +$7.05M |
|
|
18
Teladoc Health
TDOC
$1.37B
| $77.1M | 1.43% | 1,139,057 -295,955 | -21% | -$20M |
|
19
Moderna
MRNA
$9.37B
| $77.1M | 1.43% | 4,844,081 +119,835 | +3% | +$1.91M |
|
20
Elevance Health
ELV
$71.8B
| $73.5M | 1.37% | 306,106 -54,633 | -15% | -$13.1M |
|
21
Exelixis
EXEL
$10.1B
| $68.2M | 1.27% | 3,858,700 -20,100 | -0.5% | -$355K |
|
|
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $67.4M | 1.25% | 1,292,513 +27,600 | +2% | +$1.44M |
|
23
MacroGenics
MGNX
$112M
| $65.4M | 1.22% | 5,125,564 +730,300 | +17% | +$9.32M |
|
24
Illumina
ILMN
$15.8B
| $63.1M | 1.17% | 207,332 -20,859 | -9% | -$6.35M |
|
25
Humana
HUM
$36.5B
| $62M | 1.15% | 242,673 +1,461 | +0.6% | +$374K |
|